Metabolomic approach to Alzheimer’s disease diagnosis based on mass spectrometry

Blennow, K. (2004). Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. The American Society for Experimental NeuroTherapeutics, 1, 213–225. DOI: 10.1602/neurorx.1.2.213. Bruce, S. J., Tavazzi, I., Parisod, V., Rezzi, S, Kochhar, S., & Guy, P. A. (2009). Investigation of human blood plasma sample preparation for performing metabolomics using ultrahigh performance liquid chromatography/mass spectrometry. Analytical Chemistry, 81, 3285–3296. DOI: 10.1021/ac8024569. Chen, C. P. L. H., Alder, J. T., Bowen, D. M., Esiri, M. M., McDonald, B., Hope, T., Jobst, K. A., & Francis, P. T. (1996). Presynaptic serotonergic markers in communityacquired cases of Alzheimer’s disease: Correlations with depression and neuroleptic medication. Neurochemistry, 66, 1592–1598. DOI: 10.1046/j.1471-4159.1996.66041592.x. Conquer, J. A., Tierney, M. C., Zecevic, J., Bettger, W. J., & Fisher, R. H. (2000). Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids, 35, 1305–1312. DOI: 10.1007/s11745-000-0646-3. Dyrks, T., Weidemann, A., Multhaup, G., Salbaum, J. M., Lemaire, H. G., Kang, J., Müller-Hill, B., Masters, C. L., & Beyreuther, K. (1988). Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer’s disease. EMBO Journal, 7, 949–957. Goldsmith, P., Fenton, H., Morris-Stiff, G., Ahmad, N., Fisher, J., & Prasad, K. R. (2010). Metabonomics: A useful tool for the future surgeon. Journal of Surgical Research, 160, 122–132. DOI:10.1016/j.jss.2009.03.003. Grammas, P. (2011). Neurovascular dysfunction, inflammation and endothelial activation: Implications for the pathogenesis of Alzheimer’s disease. Journal of Neuroinflammation, 8, 26. DOI:10.1186/1742-2094-8-26. Klein, J. (2000). Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. Journal of Neural Transmission, 107, 1027–1063. DOI:10.1007/s007020070051. Martín-Carrasco, M. (2009). Biomarcadores en la enfermedad de Alzheimer: definición, significación diagnóstica y utilidad clínica. Psicogeriatría, 1, 101–114. Maruszak, A., & Żekanowski, C. (2011). Mitochondrial dysfunction and Alzheimer’s disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35, 320–330. DOI:10.1016/j.pnpbp.2010.07.004. McKahnn, G., Drachman, D., & Folstein, M. (1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology, 34, 939–944. DOI: 10.1212/01.wnl.0000400650.92875.cf. Mielke, M. M., & Lyketsos, C. G. (2006). Lipids and the pathogenesis of Alzheimer’s disease: Is there a link? International Review of Psychiatry, 18, 173–186. DOI: 10.1080/09540260600583007. Migliore, L., Fontana, I., Colognato, R., Coppede, F., Siciliano, G., & Murri, L. (2005). Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer’s disease and in other neurodegenerative diseases. Neurobiology of Aging, 26, 587–595. DOI:10.1016/j.neurobiolaging.2004.10.002. Nagy, Z., Esiri, M. M., Jobst, K., Morris, J. H., King, E. M. F., McDonald, B., Litchfield, S., Smith, A., Barnetson, L., & Smith, A. D. (1995). Relative role of plaques and tangles in the dementia of Alzheimer disease: Correlations using three sets of neuropathological criteria. Dementia, 6, 21–31. DOI: 10.1159/000106918. Nicholson, J. K., Lindon, J. C., & Holmes, E. (1999). “Metabonomics”: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica, 29, 1181–1189. DOI: 10.1080/004982599238047. Nitsch, R. M., Blusztajn, J. K., Pittas, A. G., Slack, B. E., Growdon, J. H., & Wurtman, R. J. (1992). Evidence for a membrane defect in Alzheimer disease brain. Procedings of the National Academy of Sciences of the United States of America, 89, 1671–1675. DOI: 10.1073/pnas.89.5.1671. Pettegrew, J. W., Panchalingam, K., Moossy, J., Martinez, J., Rao, G., & Boller, F. (1988) Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer’s disease. Archives of Neurology, 45, 1093–1096. Pulfer, M., & Murphy, R. C. (2003). Electrospray mass spectrometry of phospholipids. Mass Spectrometry Reviews, 22, 332–364. DOI: 10.1002/mas.10061. Salek, R. M., Xia, J., Innes, A., Sweatman, B. C., Adalbert, R., Randle, S., McGowan, E., Emson, P. C., & Griffin, J. L. (2010). A metabolomic study of the CRND8 transgenic mouse model of Alzheimer’s disease. Neurochemistry International, 56, 937–947. DOI:10.1016/j.neuint.2010.04.001. Scheneider, P., Hampel, H., & Buerger, K. (2009). Biological marker candidates of Alzheimer’s disease in blood, plasma, and serum. CNS Neuroscience & Therapeutics, 15, 358–374. DOI: 10.1111/j.1755-5949.2009.00104.x. Selkoe, D. J. (2004a). Alzheimer’s disease: Mechanistic understanding predicts novel therapies. Annals of Internal Medicine, 140, 627–638. Selkoe, D. J. (2004b). Cell biology of protein misfolding: The examples of Alzheimer’s and Parkinson’s disease. Nature Cell Biology, 6, 1054–1061. DOI: 10.1038/ncb1104-1054. Storga, D., Vrecko, K., Birkmayer, J. G. D., & Reibnegger, G. (1996). Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neuroscience Letters, 203, 29–32. DOI: 10.1016/0304-3940(95)12256-7. Trygg, J., Holmes, E., & Lundstedt, T. (2007). Chemometrics in metabonomics. Journal of Proteome Research, 6, 469–479. DOI: 10.1021/pr060594q. Valls-Pedret, C., Molinuevo, J. L., & Rami, L. (2010). Diagnostico precoz de la enfermedad de Alzheimer: fase prodromica y preclinica. Revista de Neurología, 51, 471–480. Ward, M. (2007). Biomarkers for Alzheimer’s disease. Expert Review of Molecular Diagnostics, 7, 635–646. DOI: 10.1586/14737159.7.5.635.